

Merck says FDA reviewing its ragweed allergy therapy

May 8 2013, by The Associated Press

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.

Merck's latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue. Patients in studies of the tablet took it daily for a year.

It could become an alternative to months of uncomfortable allergy shots. Both methods gradually desensitize the immune system to the substance triggering the allergic reaction.

In March, the Whitehouse Station, N.J., company said the [FDA](#) was reviewing its application for an immunotherapy tablet for grass pollen allergies.

[Merck](#) expects FDA rulings on both still-unnamed treatments in 2014's first half.

© 2013 The Associated Press. All rights reserved.

Citation: Merck says FDA reviewing its ragweed allergy therapy (2013, May 8) retrieved 9 April 2024 from <https://medicalxpress.com/news/2013-05-merck-fda-ragweed-allergy-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.